# Belzupacap sarotalocan

Source: https://onco.cc/drugs/belzupacap-sarotalocan/  
OnCo record `belzupacap-sarotalocan` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Belzupacap sarotalocan is an experimental virus-like drug conjugate from Aura Biosciences, in phase 3 trials for choroidal melanoma, metastases to the choroid and ocular surface tumours and other cancers.

## Summary

Belzupacap sarotalocan (AU-011, bel-sar) is a virus-like drug conjugate (light-activated) from Aura Biosciences. A virus-like particle joined to a light-sensitive dye. When an ophthalmic laser shines 689 nm infrared light on the tumour, it releases reactive oxygen species that kill tumour cells, and this is followed by an anti-tumour immune response. Its furthest stage is phase 3, for choroidal melanoma (early, and indeterminate lesions), metastases to the choroid, ocular surface tumours and non-muscle-invasive bladder cancer. ClinicalTrials.gov registers it in 5 studies linked below. Global phase 3 CoMpass (NCT06007690) in early choroidal melanoma, active not recruiting; phase 2 in metastases to the choroid (NCT06643884) recruiting; phase 1 in non-muscle-invasive bladder cancer (NCT05483868) active not recruiting; first-in-human study in ocular surface tumours per company site. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-11-03
- Also known as: AU-011; bel-sar
- Tags: pipeline; ctgov-ingest
- Code: AU-011
- Modality: Virus-like drug conjugate (light-activated)
- Mechanism: A virus-like particle joined to a light-sensitive dye. When an ophthalmic laser shines 689 nm infrared light on the tumour, it releases reactive oxygen species that kill tumour cells, and this is followed by an anti-tumour immune response.

## Sources

- Aura Biosciences: aurabiosciences.com: https://www.aurabiosciences.com/vdc-platform/our-candidate-belzupacap-sarotalocan-bel-sar/
- Aura Biosciences: aurabiosciences.com: https://www.aurabiosciences.com/vdc-platform/our-candidate-belzupacap-sarotalocan-bel-sar/
- Aura Biosciences: aurabiosciences.com: https://www.aurabiosciences.com/pipeline-programs/choroidal-melanoma/
- Aura Biosciences: aurabiosciences.com: https://www.aurabiosciences.com/vdc-platform/
- ClinicalTrials.gov: trials of AU-011: https://clinicaltrials.gov/search?intr=AU-011

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-muscle-invasive bladder cancer](https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- companies: [Aura Biosciences](https://onco.cc/companies/aura-biosciences/)
- trials: [A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer](https://onco.cc/trials/nct05483868/), [A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma](https://onco.cc/trials/nct06007690/), [Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma](https://onco.cc/trials/nct04417530/), [Study in Subjects With Small Primary Choroidal Melanoma](https://onco.cc/trials/nct03052127/), [Suprachoroidal Administration in Subjects With Metastases to the Choroid](https://onco.cc/trials/nct06643884/)

---
JSON: https://onco.cc/api/v1/entities/belzupacap-sarotalocan.json